Twist Bioscience (TWST) Stock Could Be 16% Undervalued On DNA Synthesis Market Outlook

Twist Bioscience has seen its share price move sharply in recent years, which puts the spotlight squarely on one question for investors who care about cash flows. Is the current valuation supported by what this business is expected to generate in actual dollars over time, or is the market getting ahead of itself?

• Over the past 3 years, Twist Bioscience has delivered a share price return of about 7x. This raises the stakes on whether its future cash flows can underpin that kind of move.
• The company is featured in recent research on the expanding DNA synthesis market, which may support expectations for revenue scale and future cash generation if Twist Bioscience can capture a meaningful share of that demand.
• What if you looked at Twist Bioscience through its sales instead? See why Twist Bioscience's 24.3x P/S tells a different valuation story.

The issue now is whether Twist Bioscience's current share price can be justified by the cash flows implied by a Discounted Cash Flow (DCF) intrinsic value estimate.

If you want to stress test this same cash flow question beyond Twist Bioscience, filter for other companies using 33 high quality undervalued stocks.

Does Twist Bioscience Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here is built around future free cash that Twist Bioscience could return to shareholders. The latest twelve-month free cash flow shows a loss of $78.1 million, so the whole framework depends on the business shifting from cash burn to cash generation over time.

Analyst and model projections in the DCF assume recovering and then growing free cash flows through the early 2030s, which implies a much more cash-productive Twist Bioscience than today. Those cash flow estimates put the intrinsic value meaningfully above the current share price of $166.99. Because Twist Bioscience is investing heavily to scale DNA synthesis capacity, the recent research highlighting a larger market opportunity helps explain why the stock can still trade below what the DCF model suggests. Find out what Twist Bioscience could be worth using our Discounted Cash Flow (DCF) estimate.

The Twist Bioscience Narrative: What Would Justify Today's Price?

Narratives on Twist Bioscience pick up where the DCF puzzle leaves off by laying out the specific paths for growth, margins and earnings that would need to unfold for the stock to trade meaningfully higher or lower than it does today on Simply Wall St's Community page. Each scenario links a fair value estimate to a defined mix of potential catalysts and risks, so you can track over time which version of Twist Bioscience's story is actually taking shape.

One of the top community narratives on Twist Bioscience: 59% overvalued

"Bearish analysts, while raising targets, flag that the stock has already delivered a very large year to date gain..."

Discover why this Narrative puts Twist Bioscience at 59% overvalued.

The open question on Twist Bioscience that valuation alone cannot answer

Price and cash flow expectations only tell part of the story for Twist Bioscience, as internal checks have surfaced specific concerns that informed investors may want to review before drawing their own conclusion. Take a closer look at 3 warning signs before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com